Apellis Pharmaceuticals, Inc.

APLS

$20.10

Name : Apellis Pharmaceuticals, Inc.

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $2,543,156,992.00

EPSttm : 0.36

Apellis Pharmaceuticals, Inc.

$20.10

1.13%

$0.23

Float Short %

14.54

Margin Of Safety %

-8

Put/Call OI Ratio

0.22

EPS Next Q Diff

-2.19

EPS Last/This Y

1.87

EPS This/Next Y

-1.42

Price

20.09

Target Price

35.39

Analyst Recom

Performance Q

-24.68

Relative Volume

0.85

Beta

0.37

Ticker: APLS

21 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-10-20	APLS	27.07	0.17	0.54	52026
2025-10-21	APLS	28.32	0.18	0.26	52649
2025-10-22	APLS	28.13	0.17	1.30	52334
2025-10-23	APLS	28.6	0.17	0.13	52672
2025-10-24	APLS	28.16	0.17	0.48	52699
2025-10-27	APLS	29.78	0.17	0.93	52697
2025-10-28	APLS	30.07	0.17	0.71	52846
2025-10-29	APLS	30.09	0.18	0.11	53521
2025-10-30	APLS	20.71	0.18	0.04	53685
2025-10-31	APLS	21.46	0.18	0.49	58449
2025-11-03	APLS	20.69	0.18	0.20	60006
2025-11-04	APLS	20.49	0.18	10.13	60844
2025-11-05	APLS	19.95	0.19	0.14	61328
2025-11-06	APLS	19.71	0.19	0.41	61352
2025-11-07	APLS	19.27	0.19	0.14	61365
2025-11-10	APLS	19.01	0.19	0.89	61670
2025-11-11	APLS	19.51	0.20	0.54	62151
2025-11-12	APLS	19.94	0.20	6.64	62166
2025-11-13	APLS	19.83	0.22	0.18	63296
2025-11-14	APLS	20.33	0.22	0.68	63736
2025-11-17	APLS	20.09	0.22	0.44	63768
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

21 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-10-20	APLS	27.07	276.6	31.7	-0.50
2025-10-21	APLS	28.32	276.6	39.3	-0.50
2025-10-22	APLS	28.14	304.7	46.1	-0.34
2025-10-23	APLS	28.63	304.7	43.0	-0.34
2025-10-24	APLS	28.15	304.7	47.4	-0.34
2025-10-27	APLS	29.79	304.7	37.8	-0.34
2025-10-28	APLS	30.05	304.7	44.1	-0.34
2025-10-29	APLS	30.06	304.7	45.3	-0.34
2025-10-30	APLS	20.73	304.7	86.2	-0.34
2025-10-31	APLS	21.46	304.7	40.8	-0.34
2025-11-03	APLS	20.69	-4.5	-221.8	-0.17
2025-11-04	APLS	20.48	-4.5	-225.3	-0.17
2025-11-05	APLS	19.94	-4.5	-223.2	-0.17
2025-11-06	APLS	19.71	-4.5	-225.0	-0.17
2025-11-07	APLS	19.26	-4.1	-223.6	-0.17
2025-11-10	APLS	19.00	-33.5	-224.8	-0.17
2025-11-11	APLS	19.51	-32.6	-230.2	0.27
2025-11-12	APLS	20.02	-32.6	-230.2	0.27
2025-11-13	APLS	19.83	-32.6	-225.4	0.27
2025-11-14	APLS	20.33	-32.6	-230.1	0.27
2025-11-17	APLS	20.09	-32.6	-225.1	0.27
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-10-20	APLS	-2.51	1.49	20.17
2025-10-21	APLS	-2.51	1.49	20.16
2025-10-22	APLS	-2.52	1.49	20.16
2025-10-23	APLS	-2.56	1.49	20.16
2025-10-24	APLS	-2.56	1.49	20.16
2025-10-27	APLS	-2.56	1.13	17.30
2025-10-28	APLS	-2.56	1.13	17.30
2025-10-29	APLS	-2.56	1.13	17.30
2025-10-30	APLS	-2.56	1.13	17.30
2025-10-31	APLS	-2.56	1.13	17.30
2025-11-03	APLS	-2.56	1.68	17.27
2025-11-04	APLS	-2.56	1.68	17.27
2025-11-05	APLS	-2.56	1.68	17.27
2025-11-06	APLS	-2.56	1.68	17.27
2025-11-07	APLS	-2.56	1.68	17.27
2025-11-10	APLS	-2.56	2.96	17.27
2025-11-11	APLS	-2.56	2.96	17.27
2025-11-12	APLS	-2.56	2.96	14.54
2025-11-13	APLS	-2.56	2.96	14.54
2025-11-14	APLS	-2.56	2.96	14.54
2025-11-17	APLS	-2.56	16.19	14.54
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

1.67

Avg. EPS Est. Current Quarter

-0.38

Avg. EPS Est. Next Quarter

-0.52

Insider Transactions

-2.56

Institutional Transactions

16.19

Beta

0.37

Average Sales Estimate Current Quarter

202

Average Sales Estimate Next Quarter

195

Fair Value

18.39

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

78.8

Max Drawdown 5-Year %

-82.5

Target Price

35.39

P/E

67.7

Forward P/E

PEG

1.04

P/S

2.5

P/B

6.34

P/Free Cash Flow

32.34

EPS

0.3

Average EPS Est. Cur. Y

0.27

EPS Next Y. (Est.)

-1.15

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

4.43

Relative Volume

0.85

Return on Equity vs Sector %

-15.7

Return on Equity vs Industry %

-0.8

EPS 1 7Days Diff

0.6

EPS 1 30Days Diff

0.53

EBIT Estimation

-225.1

Apellis Pharmaceuticals, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 705

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, hematopoietic stem cell transplantation-associated thrombotic microangiopathy, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

stock quote shares APLS – Apellis Pharmaceuticals, Inc. Stock Price stock today

news today APLS – Apellis Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch APLS – Apellis Pharmaceuticals, Inc. yahoo finance google finance

stock history APLS – Apellis Pharmaceuticals, Inc. invest stock market

stock prices APLS premarket after hours

ticker APLS fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: APLS

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y